Larvol Delta - A-Phase-II-Clinical-Trial-of-AntiEGFR-Antibodydrug-Conjugate-ADC-Combined-With-or-Without-Immune-Checkpoint-Inhibitors-in-the-Neoadjuvant-Treatment-of-Resectable-Locally-Advanced-Head-and-Neck-Squamous-Cell-Carcinoma

Idafang (ivonescimab) - Summit Therapeutics

Anniko (penpulimab-kcqx) - Akesobio, Sino Biopharm

Meiyouheng (becotatug vedotin) - Lepu Biopharma

http://clinicaltrials.gov/ct2/show/NCT07381075

Sep 12, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next